What is tap detection?

TAP, or tumor abnormal protein, is a secretion produced by abnormal cell proliferation and is also a means of genetic testing. Early detection can determine the approximate time before cells become cancerous, providing an effective means for diagnosing cancer and tumors. Because the TAP detection technology is simple to operate and has high sensitivity, it is of great help in the early diagnosis of cancer and tumors, as well as in the screening of patients.

Tap detection principle:

The test only requires a drop of blood, and within 15 minutes you can find out how close you are to cancer. Through the combination of lectins, multiple abnormal sugar chain proteins are recognized simultaneously, a multi-level coupling reaction occurs, and then they condense with calcium-histone into giant crystal-like particles. TAP detection technology highly aggregates dozens of abnormal sugar chain proteins such as AFP and CA series carbohydrate antigens in the same reaction system, greatly amplifying tumor signals, overcoming the defect that conventional tumor markers can only detect a few abnormal protein sugar chain proteins, and greatly improving the sensitivity of tumor detection. Abnormal sugar chain glycoproteins are closely related to tumors. The detection will highly aggregate multiple abnormal sugar chain glycoproteins in the same reaction system. TAP has a particularly high sensitivity and can effectively screen and concentrate high-risk tumor populations from a large number of asymptomatic physical examination populations. Combined with physical symptoms, medical history and other test indicators, high-risk populations with positive TAP test results will undergo further detailed examinations to detect tumors at an early stage. In the early stages of cancer, although the changes in any tumor marker are relatively small and difficult to detect early, the TAP test is not targeted at a single tumor marker, but rather a highly concentrated collection of multiple tumor markers such as AFP, CEA, CA199, etc. in the same reaction system.

The difference between Tap testing and genetic testing:

TAP testing can effectively concentrate high-risk groups for tumors, has a more obvious tumor screening effect, has a low false negative rate, and can detect tumors at an early stage; genetic testing can be applied to healthy people and patients with existing tumors. Healthy people can discover potential disease factors and occurrence probabilities in genes in advance, and prevent the occurrence of tumors or other diseases in advance; for patients who already have tumors, it can play a relevant guiding role in clinical treatment.

Widely used in:

1. Tumor auxiliary diagnosis, efficacy evaluation and recurrence and metastasis monitoring are "beneficial supplements" to pathological diagnosis and tumor marker detection, improving the accuracy of tumor diagnosis.

2. Tumor screening for clinical patients and people undergoing physical examinations to reduce missed tumors and detect tumors at an early stage.

3. Tumor risk assessment of chronic diseases and abnormal signs, early warning of tumor risk, active diagnosis and treatment, avoidance of development into mid- to late-stage tumors, and saving lives.